Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 340,706,592
  • Shares Outstanding, K 1,765,868
  • Annual Sales, $ 54,318 M
  • Annual Income, $ 4,863 M
  • 60-Month Beta 0.64
  • Price/Sales 6.29
  • Price/Cash Flow 12.38
  • Price/Book 50.69
Trade ABBV with:

Options Overview Details

View History
  • Implied Volatility 20.15% ( -0.88%)
  • Historical Volatility 14.51%
  • IV Percentile 54%
  • IV Rank 31.62%
  • IV High 29.42% on 04/12/24
  • IV Low 15.86% on 03/01/24
  • Put/Call Vol Ratio 0.99
  • Today's Volume 8,387
  • Volume Avg (30-Day) 13,041
  • Put/Call OI Ratio 0.88
  • Today's Open Interest 377,966
  • Open Int (30-Day) 355,468

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 2.95
  • Number of Estimates 10
  • High Estimate 3.00
  • Low Estimate 2.92
  • Prior Year 2.95
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
191.27 +1.18%
on 09/12/24
199.95 -3.21%
on 09/03/24
-3.35 (-1.70%)
since 08/19/24
3-Month
163.52 +18.35%
on 07/03/24
199.95 -3.21%
on 09/03/24
+22.16 (+12.93%)
since 06/18/24
52-Week
135.85 +42.45%
on 11/09/23
199.95 -3.21%
on 09/03/24
+40.03 (+26.08%)
since 09/19/23

Most Recent Stories

More News
2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market Again

For over a decade, these two drugmakers consistently outperformed the benchmark index and could do it again.

ABBV : 193.90 (+0.50%)
AZN : 79.16 (+0.74%)
Can AbbVie Regain Its Status As a Top Dividend Growth Stock?

The dividend growth powerhouse is turning the corner.

ABT : 113.75 (-0.98%)
ABBV : 193.90 (+0.50%)
Investing in Biotech or Pharma Stocks? Pay Attention to These 3 Things and You'll Win More

Financial factors aren't the only things that are worth paying attention to.

MRNA : 69.25 (-0.87%)
ABBV : 193.90 (+0.50%)
3 Stocks to Buy and Hold Forever

These stocks are built for the long run.

ABT : 113.75 (-0.98%)
ABBV : 193.90 (+0.50%)
LLY : 913.92 (+0.99%)
VRTX : 480.22 (+1.28%)
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever

Their dividends are solid. And their businesses are built for the long run.

ABBV : 193.90 (+0.50%)
BIP : 33.70 (+3.47%)
BIPC : 42.25 (+1.95%)
VZ : 43.60 (-0.64%)
TEVA Stock Rises 72.5% This Year: Time to Buy, Sell or Hold?

Teva Pharmaceutical Industries Limited’s TEVA stock has risen 72.5% so far this year compared with an increase of 17.9% for the industry. The stock has also outperformed the sector and the S&P 500, as...

SNY : 58.27 (+1.39%)
JNJ : 165.52 (-0.38%)
TEVA : 17.83 (-0.28%)
ABBV : 193.90 (+0.50%)
Is This Company Still a Strong Buy After Tripling the S&P 500's Returns?

The stock has been a winner, but there may be better times ahead for buying.

ABBV : 193.90 (+0.50%)
FDA Grants Label Expansion to J&J's Tremfya in Ulcerative Colitis

Johnson & Johnson JNJ announced that the FDA approved its blockbuster immunology medicine, Tremfya (guselkumab), for a third indication. The drug is approved to treat adults with moderately to severely...

JNJ : 165.52 (-0.38%)
LLY : 913.92 (+0.99%)
ABBV : 193.90 (+0.50%)
Is Bristol-Myers Squibb Stock Underperforming the S&P 500?

Bristol-Myers Squibb has underperformed the S&P 500 over the past year, and analysts are cautious about the stock’s prospects.

BMY : 49.52 (-0.44%)
$SPX : 5,720.90 (+1.83%)
ABBV : 193.90 (+0.50%)
Health Canada Approves AbbVie's CONSTELLA® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients 6 to 17 Years of Age

/CNW/ - AbbVie (NYSE: ABBV), today announced that Health Canada has approved CONSTELLA® (linaclotide) as a once-daily oral treatment for children and...

ABBV : 193.90 (+0.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 198.89
2nd Resistance Point 197.23
1st Resistance Point 195.09
Last Price 193.90
1st Support Level 191.29
2nd Support Level 189.63
3rd Support Level 187.48

See More

52-Week High 199.95
Last Price 193.90
Fibonacci 61.8% 175.46
Fibonacci 50% 167.90
Fibonacci 38.2% 160.34
52-Week Low 135.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar